Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study

Blood Adv. 2020 Oct 13;4(19):4618-4622. doi: 10.1182/bloodadvances.2020002269.

Abstract

  1. Shingrix is poorly immunogenic following allogeneic hematopoietic cell transplantation independent of age, CD4, and B-cell recovery.

  2. In hematopoietic cell transplantation recipients with antibody response to the vaccine, varicella zoster virus reactivation risk is not null.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hematopoietic Stem Cell Transplantation*
  • Herpes Zoster Vaccine*
  • Herpes Zoster*
  • Humans
  • Pilot Projects
  • Vaccines, Synthetic

Substances

  • Herpes Zoster Vaccine
  • Vaccines, Synthetic